XIAP与Suvivin蛋白在弥漫性大B细胞淋巴瘤中的表达及其临床病理意义

 目的　研究XIAP在弥漫性大B细胞淋巴瘤（DLBCL）中的表达及其与Suvivin表达的相关性，并探讨其与临床预后的关系。方法　采用免疫组织化学法检测49例DLBCL中XIAP与Suvivin蛋白的表达水平。结果　XIAP、Suvivin蛋白在DLBCL中的阳性表达率分别为40.8 %（20／49）和44.9 %（22／49），高于良性淋巴结病变中阳性表达率，分别为15 %（3／20）和10 %（2／20），差异均有统计学意义（P＜0.05）；XIAP与Suvivin表达呈正相关（r＝0.382，P＝0.01）；XIAP表达的DLBCL患者的平均生存时间明显短于无表达的患者（P＜0.02）。结论　XIAP蛋白表达上调可能是DLBCL发生、发展的重要因素，并可能在抑制细胞凋亡过程中与Suvivin起协同作用，并可能是DLBCL一个新的预后不良因子。

Expression of XIAP and survivin and its significance in diffuse large B-cell lymphoma

Objective To investigate the expression of XIAP and survivin and its significance in diffuse large B-cell lymphoma. Methods The expression of XIAP and survivin were detected by immunohistochemistry in 49 patients with diffuse large B-cell lymphomas. Results The positive rate of XIAP and survivin in cases of DLBCL were 40.8%(20/49) and 44.9%(22/49) respectively, which was higher than that of benign lymph node pathological changes (P ＜0.05). The expression of XIAP in DLBCL positively correlated with the expression of surviving (r =0.382, P =0.01). Moreover, the mean survival period in DLBCL expressing XIAP was shorter than the XIAP-negative group. Conclusion The up-regulation of expression of XIAP may play an important role in the development of DLBCL, and may cooperate with the expression of survivin in apoptosis pathway. Furthermore, the expression of XIAP might be a new unfavorable prognosis factor of DLBCL.